There’s a rule in American healthcare designed to protect you. It’s called the Medical Loss Ratio — MLR for short — and it says that health insurers must spend at least 80 to 85 cents of every premium dollar on actual medical care, not on executive salaries, administrative bloat, or profit. If they fall short, they owe you a rebate.

It’s one of the few concrete protections the Affordable Care Act put in consumers’ hands.

It also has a hole in it you could drive a pharmaceutical company through.

The hole is called vertical integration. And the three companies that control roughly 80 percent of your prescription drug benefits have spent the last decade climbing through it.[1]

Same Company, Every Step

When you fill a prescription, you probably think of your pharmacy benefit manager — your PBM — as a single entity doing a single job. It negotiates drug prices, processes your claim, manages the list of covered drugs. Fine. One company, one function.

That’s not what you’re actually dealing with.

Take UnitedHealth Group. When you’re covered through an employer that uses UnitedHealthcare and OptumRx, here’s what UnitedHealth Group owns at each step of your prescription’s journey: the insurer (UnitedHealthcare), the ASO/TPA platform that processes your employer’s claims (UMR), the PBM that decides which drugs are covered and at what price (OptumRx), the group purchasing organization that negotiates manufacturer contracts (EMISAR), the specialty pharmacy that dispenses the expensive drugs (Optum Specialty Pharmacy and Optum Frontier Therapies), long-term care pharmacy operations (genOa healthcare, PharmScript), and the primary care doctor’s office where the prescription originates (Optum, including Conviva Senior Primary Care).[2]

Your insurer and your PBM and your pharmacy are the same company. The organization that decides your drug is covered, decides what it costs, and then sells it to you through a pharmacy it also owns — that’s one entity. One set of shareholders. One profit motive applied at every point where money changes hands.

CVS Health runs the same play. Aetna covers you. CVS Caremark manages your drug benefit. CVS Specialty fills your specialty prescription. CVS pharmacy fills your regular one. MinuteClinic or Oak St. Health sees you when you’re sick. Signify Health monitors your chronic conditions at home. All CVS Health.[2]

Cigna’s Evernorth has a wrinkle none of the others have matched: it also owns CuraScript SD, a wholesale drug distributor. That means Cigna/Evernorth touches the supply chain one layer upstream of where the other two operate — buying drugs from manufacturers and selling them into its own network.[2]

The industry has a neutral term for this arrangement. They call it “vertical integration.” The more accurate description is a vertically integrated conflict of interest at every point of contact between you and your medication.

The MLR Escape Hatch

Here’s where it gets specific — and where your consumer protection disappears.

The MLR rule is real. Insurers subject to it cannot legally keep more than 15 to 20 cents on the dollar as profit and overhead. But MLR applies to the insurer, not to the insurer’s parent company and all its subsidiaries. A vertically integrated conglomerate can comply with MLR at the insurance entity level while shifting profits to affiliated businesses that face no such constraint.

A February 2026 actuarial analysis by Milliman, commissioned by PhRMA (the drug manufacturer lobby, with its own interests in weakening PBMs — noted), examined exactly this mechanism.[3] The paper identified two pharmacy-relevant tactics that vertically integrated organizations use to reshape MLR calculations: overpaying affiliated providers at rates that count as “medical spending” inside the regulated entity, and retaining rebates within the corporate structure rather than passing them to the insurer’s book of business.

The net effect, as the Milliman authors wrote: profits can be shifted away from the regulated insurance entity to affiliated businesses not subject to MLR limits. The savings from vertical integration — the efficiency gains the industry loves to advertise — flow upward to the parent, not outward to patients in the form of lower premiums.[3]

In plain terms: the rule that says 80 cents of your premium dollar must go to healthcare? It’s calculated at a subsidiary level, while the conglomerate above it captures margin the rule was never designed to reach.

A peer-reviewed Health Affairs analysis reached similar conclusions independently of the PhRMA-commissioned work, providing corroboration that the mechanism is real and not merely a manufacturer talking point.[4]

The Transparency Problem Is the Business Model

There’s a reason you can’t find out what your PBM paid the pharmacy for your drug, what rebate it kept from the manufacturer, or how much of your premium dollar ended up as profit at a related entity rather than in your care.

That opacity is structural. It isn’t an oversight or a bureaucratic lag. In a vertically integrated system, transparency is the one thing that makes the arbitrage visible — and visible arbitrage is regulable arbitrage. The data flows between affiliated entities as intercompany transactions, invisible to plan sponsors, invisible to regulators looking only at the insurance subsidiary, and invisible to patients.

Drug Channels Institute, the industry’s most rigorous independent data source, noted in its 2026 update that these organizations continue to exert greater control over patient access, sites of care, and pricing — and that scrutiny of their actions continues to grow.[1] What the data can’t fully show is how profits accumulate inside the corporate structure, because the companies don’t report it that way.

There’s a name for what happens when the same entity controls both sides of a transaction and sets the price between them: a related-party transaction. In any other regulated industry, related-party transactions require disclosure, arm’s-length pricing standards, and independent audit. In the PBM industry, they’re just called operations.

The “Unwinding” Non-Story

Some coverage has noted that vertically integrated companies are beginning to divest certain assets. Cigna quietly sold its primary care clinics. Centene shed several non-core businesses. In 2024, Cigna determined that its $2.7 billion investment in VillageMD was fully impaired and took the loss.[2]

This is being framed in some quarters as the market self-correcting — proof that vertical integration is retreating under competitive and regulatory pressure.

That’s not the right read. What’s being shed are the experiments at the edges: retail clinic expansions that didn’t pencil out, primary care plays that couldn’t generate sufficient volume through captive patient referral. What isn’t being shed is the core stack — insurer, PBM, specialty pharmacy — because that’s where the money actually flows.

Meanwhile, Evernorth invested $3.5 billion in Shields Health Solutions to expand its presence in hospital-based specialty pharmacy operations.[2] UnitedHealth Group acquired CPS Solutions for the same purpose. The direction of capital tells you where the industry thinks the next margin layer is: specialty pharmacy inside health systems, the fastest-growing segment of a market already dominated by the same companies.

Vertical integration isn’t unwinding. It’s redeploying.

Why This Matters for Your Prescription

The practical consequences aren’t abstract. When the entity that decides which drugs are on your formulary also owns the specialty pharmacy that dispenses the high-cost drug that made the formulary, there is no independent check on whether that formulary decision was made in your interest or in the interest of driving volume to an affiliated pharmacy.

When the company that processes your claim also owns the mail-order pharmacy it’s directing you to use, the “cost savings” it cites for mail-order may include margin captured by the affiliated pharmacy that would otherwise have gone to an independent one.

When the insurer and the PBM are subsidiaries of the same parent, and that parent also owns the GPO negotiating manufacturer contracts, the rebates flowing through that system are intercompany transactions from start to finish — with no external party confirming the price was set at arm’s length or that the savings reached you.

The system isn’t broken. It was designed this way. And the same annual update that maps every layer of these interlocking relationships — Drug Channels Institute’s 2026 vertical integration chart — shows that the map is still growing.[1]

Sources

  1. [1] Adam J. Fein, Ph.D., “Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update,” Drug Channels Institute, April 14, 2026. https://www.drugchannels.net/2026/04/mapping-vertical-integration-of.html ↩

  2. [2] Drug Channels Institute, 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Exhibit 267 (Vertical Integration Chart), March/April 2026. https://drugchannelsinstitute.com/products/industry_report/pharmacy/ ↩

  3. [3] Michelle (Klein) Robb and Jason Karcher, “Medical Loss Ratio Requirements: Challenges Posed by Vertical Integration,” Milliman, February 9, 2026. Commissioned by PhRMA. https://www.milliman.com/en/insight/mlr-vertical-integration ↩

  4. [4] Bryce Platt, “Drug Channels News Roundup, Mid-April 2026: Vertical Integration & MLR Games,” Drug Channels, April 7, 2026 (citing Health Affairs analysis from October 2025). https://www.drugchannels.net/2026/04/drug-channels-news-roundup-mid-april.html ↩